OncoCyte Corporation (OCX)
| Previous close | 2.9300 |
| Open | 2.9000 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 2.7401 - 2.9899 |
| 52-week range | 2.0800 - 4.9000 |
| Volume | |
| Avg. volume | 62,914 |
| Market cap | 36.886M |
| Beta (5Y monthly) | 0.80 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.3700 |
| Earnings date | 07 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 4.06 |
GlobeNewswireOncocyte Reports First Quarter 2024 Financial Results
Conference Call on Wednesday, May 15, 2024 at 1:30 p.m. PT / 4:30 p.m. ETIRVINE, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the quarter ended March 31, 2024. Recent Highlights Announced global commercialization partnership with Bio-Rad Laboratories, Inc.On track to ship research use only (RUO) GraftAssure™ transplant monitoring test kits to initial customers in Asia, the U.S., and the EU in 2Q
- GlobeNewswire
Oncocyte to Announce First Quarter 2024 Financial Results
Conference Call and Webcast on Wednesday, May 15, 2024 at 1:30 p.m. PT / 4:30 p.m. ETIRVINE, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, announced today that the company will release its first quarter 2024 financial results on Wednesday, May 15, 2024, after U.S. market close. The company will host a conference call and webcast on Wednesday, May 15, 2024, at 4:30 p.m. Eastern Time to discuss its financial results and highlights. In
GlobeNewswirePRISM MarketView Spotlights Oncocyte Corporation as it Works to Disrupt the Precision Diagnostics Marketplace
NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView announces the release of an insightful interview with Oncocyte Corporation’s Chief Executive Officer, Josh Riggs, as the company works to disrupt the mature diagnostics marketplace with a nimble, capital-light approach to growth. Oncocyte (Nasdaq: OCX) has developed and is preparing to commercialize precision tests in the transplant and oncology markets. The Company’s transplant diagnostic tests, VitaGraft™ and GraftAssure™, measure the
